Resources
MYCAPSSA Brochure
If you want to take the next step in learning more about MYCAPSSA, download this helpful brochure.
Patient Communication Tools
Inform your patients about the availability and key benefits of MYCAPSSA treatment with quick, convenient letter and email guides that can be customized to your office and patients.
DOWNLOAD
Maintenance of Acromegaly Control in Patients Switching from Injectable Somatostatin Receptor Ligands to Oral Octreotide
Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: results from the phase 3, randomized, double-blind, placebo-controlled CHIASMA OPTIMAL study
Transient Permeability Enhancer® (TPE) Technology
MYCAPSSA offers oral delivery of octreotide, made possible by Transient Permeability Enhancer, TPE®, Technology. This oral octreotide delivery can help patients overcome the burden and challenges associated with injectable SSA administration, such as pain and injection site reactions.2
MYCAPSSA® Virtual Rep Detail
As the first and only FDA-approved oral SSA for appropriate patients, MYCAPSSA represents an exciting and significant advancement in the treatment of acromegaly by freeing patients from the burden of SSA injections.2 In the pivotal trial, the majority of patients who switched to MYCAPSSA twice daily from injectable SSAs experienced consistent biochemical control with mean IGF-I levels maintained within the normal range during the 9-month trial period.3 Learn more about MYCAPSSA, the TPE technology that powers it, and the efficacy and safety studies supporting MYCAPSSA in appropriate patients in this virtual rep detail.
Understanding the Management of Acromegaly with MYCAPSSA® (octreotide) Delayed-Release Oral Capsules
Hear Dr. Anthony Heaney, MD, PhD, Professor at David Geffen School of Medicine, University of California Los Angeles (UCLA), discuss the first oral treatment option for appropriate patients with acromegaly.
A Nursing Perspective: Understanding MYCAPSSA and Available Resources
Join Daphne Adelman, BSN, MBA Clinical Nurse Specialist with Chiasma as she shares an overview of the MYCAPSSA phase 3 clinical trials and safety profile, discusses how to get appropriate patients with acromegaly started on therapy and highlights the dosing and storage information for MYCAPSSA.
What MYCAPSSA® (octreotide) Delayed-Release Oral Capsules Approval Means to the Acromegaly Patient Community
Learn from Jill Sisco, President of Acromegaly Community, what the value of an oral SSA treatment option offers patients and what MYCAPSSA could mean for patients with acromegaly.
ADDITIONAL VIDEOS
Click here to watch more videos and patient experiences with acromegaly.
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.
WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.
Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.
Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.
ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.
DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.
Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.
PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.
To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.
WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.
Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.
Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.
ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.
DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.
Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.
PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.
To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
REFERENCES
1. MYCAPSSA [package insert]. Amryt Pharmaceuticals;2022. 2. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):dgaa526. 3. Samson SL, et al. J Endocr Soc.. 2021;5(suppl 1):A515-516.
©2023 Amryt Pharmaceuticals, Inc. MYCAPSSA is a registered trademark of the Amryt Pharma Group. All rights reserved. MC/US/427 07/2022